LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
XTLB
XTL Biopharmaceuticals Ltd.
There isn't enough reported data to score XTLB yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
XTLB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Stable | |
| Strong |
XTLB's balance sheet is currently strong, and its cash flow is stable, but its profitability is under pressure. There isn't enough data to rate its revenue.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
XTLB PE Valuation
XTLB has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
XTLB Forward outlook
There aren't enough analyst estimates for XTLB to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus XTLB down 155%.
XTLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$2.88 | +$2.40 |
| Q3 2024 | -$3.04 | +$3.68 |
| Q2 2024 | -$2.08 | +$6.40 |
| Q1 2024 | -$1.12 | +$7.04 |
| Q4 2023 | -$5.28 | -$1.28 |
| Q3 2023 | -$6.72 | -262% |
| Q2 2023 | -$8.48 | -266% |
| Q1 2023 | -$8.16 | -343% |
XTLB is still losing money, but far less than before: $2.88 per share over the past year, against $16.16 at its worst in early 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
XTLB Quarterly Revenue
XTLB's revenue is growing: $289,000 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -281% | N/A |
| Q3 2024 | -472% | N/A |
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
XTLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
| Q2 2024 | $0 | $0 |
| Q1 2024 | $0 | $0 |
| Q4 2023 | $0 | $0 |
| Q3 2023 | $0 | $0 |
| Q2 2023 | $0 | $0 |
| Q1 2023 | $0 | $0 |
XTLB's free cash flow has been positive every quarter for six years: $0 over the past year, against $0 the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over XTLB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
XTLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +29% | +99.5K shares |
| 1 year | +29% | +99.5K shares |
| 3 years | +22% | +79.7K shares |
| 5 years | +37% | +119K shares |
| Available history | +37% | +119K shares |
XTLB has 440,101 diluted shares, up 29% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
XTLB hasn't bought back shares in the past year.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
XTLB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | -6.6x | Net Cash |
| Q3 2018 | -0.9x | Net Cash |
| Q2 2018 | -2.6x | Net Cash |
XTLB has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
XTLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.4 | Neutral |
| Stochastic | 2.2 | Oversold |
XTLB's weekly RSI is 34 (neutral) and its Stochastic is 2 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
XTLB PE vs Healthcare Sector
| Metric | XTLB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XTLB has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over XTLB on trend strength, trading above more of its moving averages.
XTLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.89 | 13% below |
| 20 week MA | $2.39 | 31% below |
| 50 week MA | $2.69 | 39% below |
| 100 week MA | $4.01 | 59% below |
| 200 week MA | $5.16 | 68% below |
XTLB is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over XTLB on returns for 2026, with the stronger performance.
XTLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.20 | $11.0 | +112% |
| 2021 | $11.0 | $10.9 | -1.1% |
| 2022 | $10.9 | $4.76 | -56% |
| 2023 | $4.76 | $4.04 | -15% |
| 2024 | $4.04 | $8.28 | +105% |
| 2025 | $8.28 | $2.96 | -64% |
| 2026 YTD | $2.96 | $1.64 | -45% |
XTLB's yearly returns have swung widely, from +112% in 2020 to −64% in 2025. It's down 45% so far in 2026.